Top

Critical Care

Published in:

Open Access 01-08-2014 | Research

Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients

Authors: Herbert Schöchl, Wolfgang Voelckel, Marc Maegele, Lukas Kirchmair, Christoph J Schlimp

Published in: Critical Care | Issue 4/2014

Abstract

Introduction

Purified prothrombin complex concentrate (PCC) is increasingly used as hemostatic therapy for trauma-induced coagulopathy (TIC). However, the impact of PCC administration on coagulation status among patients with TIC has not been adequately investigated.

Methods

In this observational, descriptive study, data relating to thrombin generation were obtained from plasma samples gathered prospectively from trauma patients upon emergency room (ER) admission and over the following 7 days. Standard coagulation tests, including measurement of antithrombin (AT) and fibrinogen, were performed. Three groups were investigated: patients receiving no coagulation therapy (NCT group), patients receiving fibrinogen concentrate only (FC group), and patients treated with PCC and fibrinogen concentrate (FC-PCC group).

Results

The study population (77 patients) was predominantly male (84.4%); mean age was 40 ± 15 years and mean injury severity score was 25.6 ± 12.7. There were no significant differences between the three study groups in thrombin-related parameters upon ER admission. Endogenous thrombin potential (ETP) was significantly higher in the FC-PCC group compared with the NCT group on days 1 to 4 and the FC group on days 1 to 3. AT levels were significantly lower in the FC-PCC group from admission until day 3 (versus FC group) or day 4 (versus NCT group). Fibrinogen increased over time, with no significant between-group differences after ER admission. Despite ETP being higher, prothrombin time and activated partial thromboplastin time were significantly prolonged in the FC-PCC group from admission until day 3 to 4.

Conclusions

Treatment with PCC increased ETP for several days, and patients receiving PCC therapy had low AT concentrations. These findings imply a potential pro-thrombotic state not reflected by standard coagulation tests. This is probably important given the postoperative acute phase increase in fibrinogen levels, although studies with clinical endpoints are needed to ascertain the implications for patient outcomes. We recommend careful use of PCC among trauma patients, with monitoring and potentially supplementation of AT.

Available only for authorised users

Brohi K, Singh J, Heron M, Coats T: Acute traumatic coagulopathy. J Trauma. 2003, 54: 1127-1130. 10.1097/01.TA.0000069184.82147.06.CrossRefPubMed

Maegele M, Lefering R, Yucel N, Tjardes T, Rixen D, Paffrath T, Simanski C, Neugebauer E, Bouillon B: Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury. 2007, 38: 298-304. 10.1016/j.injury.2006.10.003.CrossRefPubMed

Johansson PI, Sørensen AM, Larsen CF, Windeløv NA, Stensballe J, Perner A, Rasmussen LS, Ostrowski SR: Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets. Transfusion. 2013, 53: 3088-3099. 10.1111/trf.12214.CrossRefPubMed

Spinella PC, Holcomb JB: Resuscitation and transfusion principles for traumatic hemorrhagic shock. Blood Rev. 2009, 23: 231-240. 10.1016/j.blre.2009.07.003.PubMedCentralCrossRefPubMed

Dirks J, Jørgensen H, Jensen CH, Ostrowski SR, Johansson PI: Blood product ratio in acute traumatic coagulopathy–effect on mortality in a Scandinavian level 1 trauma centre. Scand J Trauma Resusc Emerg Med. 2010, 18: 65-10.1186/1757-7241-18-65.PubMedCentralCrossRefPubMed

Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, Alarcon LH, Bai Y, Brasel KJ, Bulger EM, Cotton BA, Matijevic N, Muskat P, Myers JG, Phelan HA, White CE, Zhang J, Rahbar MH, PROMMTT Study Group: The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013, 148: 127-136. 10.1001/2013.jamasurg.387.PubMedCentralCrossRefPubMed

Radwan ZA, Bai Y, Matijevic N, del Junco DJ, McCarthy JJ, Wade CE, Holcomb JB, Cotton BA: An emergency department thawed plasma protocol for severely injured patients. JAMA Surg. 2013, 148: 170-175. 10.1001/jamasurgery.2013.414.PubMedCentralCrossRefPubMed

Theusinger OM, Baulig W, Seifert B, Emmert MY, Spahn DR, Asmis LM: Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Br J Anaesth. 2011, 106: 505-511. 10.1093/bja/aer003.CrossRefPubMed

Patanwala AE, Acquisto NM, Erstad BL: Prothrombin complex concentrate for critical bleeding. Ann Pharmacother. 2011, 45: 990-999. 10.1345/aph.1Q096.CrossRefPubMed

10.

Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: Clinical review: Prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011, 15: 201-10.1186/cc9311.PubMedCentralCrossRefPubMed

11.

Tanaka KA, Szlam F: Treatment of massive bleeding with prothrombin complex concentrate: argument for. J Thromb Haemost. 2010, 8: 2589-2591. 10.1111/j.1538-7836.2010.04052.x.CrossRefPubMed

12.

Schöchl H, Maegele M, Solomon C, Gorlinger K, Voelckel W: Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med. 2012, 20: 15-10.1186/1757-7241-20-15.PubMedCentralCrossRefPubMed

13.

Grassetto A, De Nardin M, Ganzerla B, Geremia M, Saggioro D, Serafini E, Zampieri S, Toffoli M, Penzo D, Bossi A, Maggiolo C: ROTEM®-guided coagulation factor concentrate therapy in trauma: 2-year experience in Venice. Italy Crit Care. 2012, 16: 428-PubMed

14.

Innerhofer P, Westermann I, Tauber H, Breitkopf R, Fries D, Kastenberger T, El Attal R, Strasak A, Mittermayr M: The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury. 2013, 44: 209-216. 10.1016/j.injury.2012.08.047.CrossRefPubMed

15.

Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C: Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010, 14: R55-10.1186/cc8948.PubMedCentralCrossRefPubMed

16.

Theusinger OM, Spahn DR, Ganter MT: Transfusion in trauma: why and how should we change our current practice?. Curr Opin Anaesthesiol. 2009, 22: 305-312. 10.1097/ACO.0b013e3283212c7c.CrossRefPubMed

17.

Godier A, Susen S, Samama CM: Treatment of massive bleeding with prothrombin complex concentrate: argument against. J Thromb Haemost. 2010, 8: 2592-2595. 10.1111/j.1538-7836.2010.04062.x.CrossRefPubMed

18.

Lin DM, Murphy LS, Tran MH: Use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review. Transfus Med Rev. 2013, 27: 91-104. 10.1016/j.tmrv.2013.01.002.CrossRefPubMed

19.

Dickneite G, Pragst I: Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth. 2009, 102: 345-354. 10.1093/bja/aen391.PubMedCentralCrossRefPubMed

20.

Honickel M, Rieg A, Rossaint R, Braunschweig T, Spronk HM, ten Cate H, van Oerle R, Tolba R, Grottke O: Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia. Thromb Haemost. 2011, 106: 724-733. 10.1160/TH11-02-0101.CrossRefPubMed

21.

Mitterlechner T, Innerhofer P, Streif W, Lödl M, Danninger T, Klima G, Hansson K, Fries D: Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J Thromb Haemost. 2011, 9: 729-737. 10.1111/j.1538-7836.2011.04211.x.CrossRefPubMed

22.

Fries D, Haas T, Klingler A, Streif W, Klima G, Martini J, Wagner-Berger H, Innerhofer P: Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy–a porcine model. Br J Anaesth. 2006, 97: 460-467. 10.1093/bja/ael191.CrossRefPubMed

23.

Bruce D, Nokes TJ: Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008, 12: R105-10.1186/cc6987.PubMedCentralCrossRefPubMed

24.

Nienaber U, Innerhofer P, Westermann I, Schöchl H, Attal R, Breitkopf R, Maegele M: The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury. 2011, 42: 697-701. 10.1016/j.injury.2010.12.015.CrossRefPubMed

25.

Schick KS, Fertmann JM, Jauch KW, Hoffmann JN: Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009, 13: R191-10.1186/cc8186.PubMedCentralCrossRefPubMed

26.

Schöchl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, Hanke A, Voelckel W, Solomon C: Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011, 15: R83-10.1186/cc10078.PubMedCentralCrossRefPubMed

27.

Grottke O, Braunschweig T, Spronk HM, Esch S, Rieg AD, van Oerle R, ten Cate H, Fitzner C, Tolba R, Rossaint R: Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood. 2011, 118: 1943-1951. 10.1182/blood-2011-03-343046.CrossRefPubMed

28.

Holley AB, Petteys S, Mitchell JD, Holley PR, Collen JF: Thromboprophylaxis and VTE rates in soldiers wounded in Operation Enduring Freedom and Operation Iraqi Freedom. Chest. 2013, 144: 966-973. 10.1378/chest.12-2879.CrossRefPubMed

29.

Geerts WH, Code KI, Jay RM, Chen E, Szalai JP: A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994, 331: 1601-1606. 10.1056/NEJM199412153312401.CrossRefPubMed

30.

Schöchl H, Voelckel W, Grassetto A, Schlimp CJ: Practical application of point-of-care coagulation testing to guide treatment decisions in trauma. J Trauma Acute Care Surg. 2013, 74: 1587-1598. 10.1097/TA.0b013e31828c3171.CrossRefPubMed

31.

Baxter: Summary of product characteristics – Prothromplex Total 600 IU. [http://mri.medagencies.org/download/AT_H_0373_001_FinalSPC.pdf]. Accessed 21 July 2014

32.

Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010, 376: 23-32.CrossRefPubMed

33.

Huber-Wagner S, Lefering R, Qvick LM, Korner M, Kay MV, Pfeifer KJ, Reiser M, Mutschler W, Kanz KG: Effect of whole-body CT during trauma resuscitation on survival: a retrospective, multicentre study. Lancet. 2009, 373: 1455-1461. 10.1016/S0140-6736(09)60232-4.CrossRefPubMed

34.

Schaden E, Hoerburger D, Hacker S, Kraincuk P, Baron DM, Kozek-Langenecker S: Fibrinogen function after severe burn injury. Burns. 2012, 38: 77-82. 10.1016/j.burns.2010.12.004.CrossRefPubMed

35.

Sørensen JV, Jensen HP, Rahr HB, Borris LC, Lassen MR, Fedders O, Haase JP, Knudsen F: Fibrinogen and fibrin derivatives in traumatized patients: relation to injury severity and posttraumatic pulmonary dysfunction. Haemostasis. 1993, 23: 91-97.PubMed

36.

Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA: Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother. 2011, 45: 869-875. 10.1345/aph.1P605.CrossRefPubMed

37.

Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN: Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study. Circulation. 2013, 128: 1234-1243.PubMed

38.

Joseph B, Amini A, Friese RS, Houdek M, Hays D, Kulvatunyou N, Wynne J, O'Keeffe T, Latifi R, Rhee P: Factor IX complex for the correction of traumatic coagulopathy. J Trauma Acute Care Surg. 2012, 72: 828-834.CrossRefPubMed

39.

Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R: Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013, 17: R76-10.1186/cc12685.PubMedCentralCrossRefPubMed

40.

Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA: Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth. 2009, 102: 793-799. 10.1093/bja/aep098.CrossRefPubMed

41.

Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ: Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther. 2007, 26: 141-148. 10.1111/j.1365-2036.2007.03369.x.CrossRefPubMed

42.

Mann KG, Brummel K, Butenas S: What is all that thrombin for?. J Thromb Haemost. 2003, 1: 1504-1514. 10.1046/j.1538-7836.2003.00298.x.CrossRefPubMed

43.

Dunbar NM, Chandler WL: Thrombin generation in trauma patients. Transfusion. 2009, 49: 2652-2660. 10.1111/j.1537-2995.2009.02335.x.CrossRefPubMed

44.

Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayr M: Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the ‘Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study’. Br J Anaesth. 2011, 107: 378-387. 10.1093/bja/aer158.CrossRefPubMed

45.

Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Hemker HC: The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002, 88: 576-582.PubMed

46.

Hanker-Dusel C, Grundmann C, Eich S, Seitz R, König H: Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis. 2004, 15: 405-411. 10.1097/01.mbc.0000114437.81125.2b.CrossRef

47.

Grundman C, Plesker R, Kusch M, Hanschmann KM, Eich S, Seitz R, Konig H: Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence. Thromb Haemost. 2005, 94: 1338-1339.PubMed

48.

Franchini M, Lippi G: Prothrombin complex concentrates: an update. Blood Transfus. 2010, 8: 149-154.PubMedCentralPubMed

49.

Grottke O, Rossaint R, Henskens Y, van Oerle R, Ten Cate H, Spronk HM: Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model. PLoS One. 2013, 8: e64100-10.1371/journal.pone.0064100.PubMedCentralCrossRefPubMed

50.

Kalina U, Bickhard H, Schulte S: Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008, 62: 1614-1622. 10.1111/j.1742-1241.2008.01859.x.CrossRefPubMed

51.

Ruttmann TG, Jamest MF, Lombard EH: Haemodilution-induced enhancement of coagulation is attenuated in vitro by restoring antithrombin III to pre-dilution concentrations. Anaesth Intensive Care. 2001, 29: 489-493.PubMed

52.

Butenas S, van't Veer C, Mann KG: “Normal” thrombin generation. Blood. 1999, 94: 2169-2178.PubMed

53.

Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012, 3: CD005011

54.

Guzzetta NA, Szlam F, Kiser AS, Fernandez JD, Szlam AD, Leong T, Tanaka KA: Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass. Br J Anaesth. 2014, 112: 319-27. 10.1093/bja/aet355.CrossRefPubMed

55.

Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I: Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007, 98: 790-797.PubMed

56.

Sniecinski R, Szlam F, Chen EP, Bader SO, Levy JH, Tanaka KA: Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. Anesth Analg. 2008, 106: 713-718. 10.1213/ane.0b013e3181608f7c.CrossRefPubMed

57.

Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G: Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999, 95: S3-S6. 10.1016/S0049-3848(99)00077-8.CrossRefPubMed

58.

Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tonnesen E, Ingerslev J, Sorensen B: Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost. 2009, 7: 795-802. 10.1111/j.1538-7836.2009.03331.x.CrossRefPubMed

59.

Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A: Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009, 102: 137-144.PubMed

60.

Solomon C, Hagl C, Rahe-Meyer N: Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth. 2013, 110: 947-956. 10.1093/bja/aes576.PubMedCentralCrossRefPubMed

61.

Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sorensen B, Hagl C, Pichlmaier M: Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013, 118: 40-50. 10.1097/ALN.0b013e3182715d4d.CrossRefPubMed

62.

Dickneite G, Pragst I, Joch C, Bergman GE: Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis. 2009, 20: 535-540. 10.1097/MBC.0b013e32832da1c5.CrossRefPubMed

63.

Martini J, Maisch S, Pilshofer L, Streif W, Martini W, Fries D: Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs. Transfusion. 2014, 54: 149-157. 10.1111/trf.12241.CrossRefPubMed

64.

Dutton RP, Parr M, Tortella BJ, Champion HR, Bernard GR, Boffard K, Bouillon B, Croce MA, Dimsits J, Holcomb JB, Leppaniemi A, Vincent JL, Hauser CJ: Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma. 2011, 71: 12-19. 10.1097/TA.0b013e31821a42cf.CrossRefPubMed

65.

Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008, 133: 381S-453S. 10.1378/chest.08-0656.CrossRefPubMed

66.

Hanke AA, Joch C, Gorlinger K: Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth. 2013, 110: 764-772. 10.1093/bja/aes501.CrossRefPubMed

Title: Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients
Authors: Herbert Schöchl
Wolfgang Voelckel
Marc Maegele
Lukas Kirchmair
Christoph J Schlimp
Publication date: 01-08-2014
Publisher: BioMed Central
Published in: Critical Care / Issue 4/2014
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc13982

At a glance: The STEP trials

Springer Medicine

Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

Glutamine – from conditionally essential to totally dispensable?

Impact of transpulmonary thermodilution-based cardiac contractility and extravascular lung water measurements on clinical outcome of patients with Takotsubo cardiomyopathy after subarachnoid hemorrhage: a retrospective observational study

A comparison of different diagnostic criteria of acute kidney injury in critically ill patients

Estimated cerebral oxyhemoglobin as a useful indicator of neuroprotection in patients with post-cardiac arrest syndrome: a prospective, multicenter observational study

Severe respiratory insufficiency during pandemic H1N1 infection: prognostic value and therapeutic potential of pulmonary surfactant protein A

The benefit of specialized team approaches in patients with acute kidney injury undergoing continuous renal replacement therapy: propensity score matched analysis